HCPLive

Finerenone Approval Expands CKD Care in Type 1 Diabetes

Sep 22, 2026 · 0:04:49

Listen to Episode

✨ AI Summary

Finerenone is the first new therapy for CKD in type 1 diabetes in 30 years.
The approval is based on dedicated trial data, not extrapolation.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FINE-ONE trial.

Guests on This Episode

researcher, ORCID id # 0000-0002-5743-9458 · 1 podcast appearance

NB

Natalie Bellini

1 podcast appearance

More from HCPLive

Subcutaneous Furosemide Bioequivalent to IV, Bioavailable Across Multiple Injection Sites

Oct 12, 2026 · 0:03:18

Targeting Senescent Cells in Actinic Keratosis With RLS-1496

Oct 12, 2026 · 0:04:25

Atopic Dermatitis Biologic Selection, With Raj Chovatiya, MD, PhD

Oct 12, 2026 · 0:03:33

Tovinontrine 50 mg Improves cGMP With Minimal Effect on NT-proBNP in HFpEF

Oct 12, 2026 · 0:06:00

View all episodes →